Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Dyax Corp. (NasdaqNM:DYAX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
One Kendall Square
Cambridge, MA 02139
Phone: (617) 225-2500
Fax: (617) 225-2501
Email: sgalliker@dyax.com
Employees (last reported count): 186
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 38%
·Over the last 6 months:
 · 2 insider buys; 12.0K shares (0.2% of insider shares)
 · 3 insider sells; 45.0K shares
  (0.6% of insider shares)
·Institutional: 29% (48% of float)
(60 institutions)
·Net Inst. Buying: 629.0K shares (+9.98%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Dyax Corp. is a biopharmaceutical company that has developed and patented a method known as phage display. The method is used to identify a range of compounds with potential for the treatment and diagnosis of diseases. The Company is also using this method to identify compounds that can be used in purifying and manufacturing biopharmaceuticals and chemicals. In addition, Dyax develops, manufactures and sells chromatography separation systems and consumables through its Biotage subsidiary. Its customers use the Company's systems and consumables in separation processes from the discovery scale, where small amounts of a compound are purified for research work, through the preparative and production scales, where a product is manufactured for commercialization. The Company is also a developer and manufacturer of chromatography systems that use disposable cartridges to purify pharmaceuticals being produced for research and clinical development.
More from Market Guide: Expanded Business Description

Financial Summary
Dyax Corp. is a biopharmaceutical company that has developed and patented a method, known as phage display, used to identify a range of compounds with potential for the treatment and diagnosis of diseases. For the six months ended 6/30/01, total revenues rose 49% to $15.3 million. Net loss fell 17% to $7.2 million. Results reflect increased revenues from research collaborations and licensing arrangements, partially offset by increased development expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Henry Blair, 57
Chairman, Pres, CEO
$475K$26K
Gregory Phelps, 52
Vice Chairman
327K34K
Stephen Galliker, 54
Exec. VP- Fin. and Admin., CFO
--  --  
Scott Chappel, Ph.D., 50
Exec. VP of Research and Technology
--  --  
David Patteson, 45
Exec. VP, Separations Division and Pres of Biotage, Inc.
269K--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:DYAXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 27-Mar-2001
$6.563
Recent Price$12.14 
52-Week High
on 3-Oct-2000
$54.125
Daily Volume (3-month avg)100.5K
Daily Volume (10-day avg)32.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-68.1%
52-Week Change
relative to S&P500
-57.1%
Share-Related Items
Market Capitalization$233.9M
Shares Outstanding19.3M
Float11.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.29 
Earnings (ttm)-$0.82 
Earnings (mrq)-$0.20 
Sales (ttm)$1.78 
Cash (mrq)$3.28 
Valuation Ratios
Price/Book (mrq)3.69 
Price/EarningsN/A 
Price/Sales (ttm)6.80 
Income Statements
Sales (ttm)$30.2M
EBITDA (ttm)-$14.5M
Income available to common (ttm)-$13.7M
Profitability
Profit Margin (ttm)-45.2%
Operating Margin (ttm)-55.7%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-18.00%
Return on Equity (ttm)-30.13%
Financial Strength
Current Ratio (mrq)6.05 
Debt/Equity (mrq)0.03 
Total Cash (mrq)$63.1M
Short Interest
As of 8-Aug-2001
Shares Short75.0K
Percent of Float0.6%
Shares Short
(Prior Month)
271.0K
Short Ratio0.81 
Daily Volume92.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.